March 10, 2020

Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters within the frames of the conference, namely:

• “Investigation of bell-shaped dose response of bispecific T-cell engaging antibodies under physiological conditions: blinatumomab case study” by Oleg Demin Jr
• “Physiologically based pharmacokinetic and receptor occupancy (PBPK/RO) modeling of anti-PD1 monoclonal antibodies” by Dmitry Shchelokov, Oleg Demin Jr
• “CYTOCON DB as a tool to collect, compare and visualize available data on immune cells and cytokine concentrations in humans” by Ekaterina Mogilevskaya
• “Exploration of structural differences between mechanism-based PK/PD and QSP models” by Oleg Demin
• “Method to describe multiple effects of regulatory molecules on cell dynamics process in QSP models of immune response” by Oleg Demin
• “QSP modeling of Combination of Radiotherapy and Immunotherapy in Pancreatic Ductal Adenocarcinoma” by Svetlana Rubina, Oleg Demin
• “Stimulation of erythropoiesis with ESA or blood donation: QSP model” by Alexander Stepanov
• “The development and management of Quantitative Systems Pharmacology modeling platforms using “Heta compiler”” by Evgeny Metelkin
• “Investigation of combination therapy by quantitative systems pharmacology model of Alzheimer’s disease” by Tatiana Karelina
• “Immune Response Template: Pre-calibrated Immune System Model for Quantitative Systems Pharmacology Development Needs” by Veronika Musatova

Still, the posters are going to be published on our website.
InSysBio team is appreciative of the organizers’ effort and their contribution to the international safety maintenance. We are looking forward to participating in QSPC next spring!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

Share